Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708264 | 0.96 | KEAP1 (0.41) | KEAP1NFE2L2TSHRKMT2AHTT | |
| SCHEMBL21708260 | 0.93 | KEAP1 (0.47) | KEAP1NFE2L2TSHRKMT2AHTT | |
| SCHEMBL21708272 | 0.93 | KEAP1 (0.42) | KEAP1NFE2L2TSHRKMT2APOLB | |
| SCHEMBL21708353 | 0.93 | KEAP1 (0.46) | KEAP1NFE2L2KMT2AMAPT | |
| SCHEMBL21708329 | 0.89 | TSHR (0.38) | KEAP1NFE2L2TSHRKMT2AHTT | |
| SCHEMBL21708295 | 0.87 | KEAP1 (0.39) | KEAP1NFE2L2TSHRKMT2APOLB | |
| SCHEMBL21708366 | 0.86 | KEAP1 (0.40) | KEAP1NFE2L2TSHRKMT2AHTT | |
| SCHEMBL21708294 | 0.84 | TGFBR1 (0.47) | KEAP1NFE2L2TSHR | |
| SCHEMBL21708321 | 0.82 | KEAP1 (0.42) | KEAP1NFE2L2TSHRKMT2AHTT | |
| SCHEMBL21708216 | 0.82 | KEAP1 (0.39) | KEAP1NFE2L2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | KEAP1 3844/4885NFE2L2 3888/4885TSHR 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.